FAQ

PF-05231023

 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2015-2017
02420152017

Related topics

Related topics

2 relations

Broader (2)

Antibodies, Monoclonal, HumanizedFibroblast Growth Factor

Related mentions per year

Related mentions per year

1974-2018
197019801990200020102020
PF-05231023
Fibroblast Growth Factor
Antibodies, Monoclonal, Humanized

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Fibroblast Growth Factor 21 Protects Photoreceptor Function in Type 1 Diabetic Mice.
Retinal neuronal abnormalities occur before vascular changes in diabetic retinopathy. Accumulating experimental evidence suggests… (More)
Is this relevant?
Review
2017
Review
2017
FGF21 and metabolic disease in 2016: A new frontier in FGF21 biology
Low amino acid levels High carbohydrate levels Fibroblast growth factor 21 (FGF21) is an endocrine hormone that regulates energy… (More)
  • figure 1
Is this relevant?
2017
2017
Once-weekly administration of a long-acting fibroblast growth factor 21 analogue modulates lipids, bone turnover markers, blood pressure and body weight differently in obese people with…
AIMS To assess the safety, tolerability, pharmacokinetics and pharmacodynamics of PF-05231023, a long-acting fibroblast growth… (More)
Is this relevant?
2016
2016
A Long-Acting FGF21 Molecule, PF-05231023, Decreases Body Weight and Improves Lipid Profile in Non-human Primates and Type 2 Diabetic Subjects.
FGF21 plays a central role in energy, lipid, and glucose homeostasis. To characterize the pharmacologic effects of FGF21, we… (More)
  • figure 1
  • figure 2
  • figure 3
  • table 1
  • figure 4
Is this relevant?
2016
2016
PF-05231023, a long-acting FGF21 analogue, decreases body weight by reduction of food intake in non-human primates
PF-05231023, a long-acting FGF21 analogue, is a promising potential pharmacotherapy for the treatment of obesity and associated… (More)
  • table 1
  • table 2
  • table 3
  • figure 2
  • figure 4
Is this relevant?
2015
2015
Pharmacokinetics and pharmacodynamics of PF-05231023, a novel long-acting FGF21 mimetic, in a first-in-human study.
AIMS The aim of the present study was to evaluate the pharmacokinetics/pharmacodynamics (PK/PD), safety and tolerability of… (More)
Is this relevant?
2015
2015
Mechanistic investigation of the preclinical pharmacokinetics and interspecies scaling of PF-05231023, a fibroblast growth factor 21-antibody protein conjugate.
PF-05231023, a long-acting fibroblast growth factor 21 (FGF21) analog, was generated by covalently conjugating two engineered… (More)
  • table 1
  • table 2
  • table 3
  • table 4
  • table 5
Is this relevant?
2015
2015
Pharmacokinetics (PK), Pharmacodynamics (PD) and Integrated PK/PD Modeling of a Novel Long Acting FGF21 Clinical Candidate PF-05231023 in Diet-Induced Obese and Leptin-Deficient Obese Mice
Pharmacological administration of fibroblast growth factor 21 (FGF21) improves metabolic profile in preclinical species and… (More)
  • table 1
  • table 2
  • figure 1
  • figure 2
  • figure 3
Is this relevant?
2015
2015
FGF21 does not require interscapular brown adipose tissue and improves liver metabolic profile in animal models of obesity and insulin-resistance
FGF21 is a key metabolic regulator modulating physiological processes and its pharmacological administration improves metabolic… (More)
  • figure 1
  • figure 2
  • table 1
  • figure 3
  • figure 4
Is this relevant?
2015
2015
Dmd061713 803..811
PF-05231023, a long-acting fibroblast growth factor 21 (FGF21) analog, was generated by covalently conjugating two engineered… (More)
  • figure 1
  • table 1
  • table 2
  • figure 2
  • figure 3
Is this relevant?